Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Current Liabilities (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Total Current Liabilities for 11 consecutive years, with $19.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 53.13% to $19.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.3 million through Dec 2025, down 53.13% year-over-year, with the annual reading at $19.3 million for FY2025, 53.13% down from the prior year.
  • Total Current Liabilities hit $19.3 million in Q4 2025 for Seres Therapeutics, down from $22.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $108.3 million in Q2 2024 to a low of $19.3 million in Q4 2025.
  • Historically, Total Current Liabilities has averaged $67.8 million across 5 years, with a median of $78.6 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: surged 106.67% in 2021 and later plummeted 71.43% in 2025.
  • Year by year, Total Current Liabilities stood at $82.3 million in 2021, then rose by 4.06% to $85.6 million in 2022, then grew by 15.26% to $98.7 million in 2023, then tumbled by 58.22% to $41.2 million in 2024, then tumbled by 53.13% to $19.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for MCRB at $19.3 million in Q4 2025, $22.4 million in Q3 2025, and $30.9 million in Q2 2025.